Wall Street Zen Upgrades Aptevo Therapeutics (NASDAQ:APVO) to Hold

Aptevo Therapeutics (NASDAQ:APVO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Aptevo Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Aptevo Therapeutics presently has an average rating of “Hold”.

Aptevo Therapeutics Trading Down 5.3%

APVO opened at $4.27 on Friday. Aptevo Therapeutics has a 1-year low of $3.95 and a 1-year high of $1,299.60. The company has a market cap of $4.27 million, a P/E ratio of 0.00 and a beta of 1.44. The company has a fifty day moving average price of $6.53 and a two-hundred day moving average price of $16.94.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Friday, March 27th. The biotechnology company reported $118.23 EPS for the quarter, beating the consensus estimate of ($8.10) by $126.33. On average, research analysts forecast that Aptevo Therapeutics will post -15.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Birchview Capital LP bought a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned about 1.32% of Aptevo Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.